Sobi Successfully Completes Issues of Class C Shares for Future Growth Initiatives

Successful Class C Shares Issues by Sobi

On May 8, 2025, the Annual General Meeting (AGM) of Swedish Orphan Biovitrum AB, commonly known as Sobi, reached a significant decision regarding its capital structure. The meeting authorized the issuance of redeemable and convertible class C shares, marking a crucial step in the company's strategy to underpin its long-term incentive programs. This initiative is aimed at ensuring that Sobi can effectively meet its financial obligations and continue its mission in the biopharmaceutical sector.

The Board of Directors, following the AGM's resolution, proposed a conditional repurchase plan for all issued class C shares. This strategy was contingent upon successful subscription and payment from Svenska Handelsbanken AB, a pivotal financial partner in this endeavor. On July 15, 2025, the Board acted on this resolution, paving the way for the financial maneuvers that would facilitate the repurchase of 1,412,788 class C shares.

Fast forward to August 21, 2025, and the subscription process has been successfully completed. Svenska Handelsbanken AB has subscribed to all the issued shares, leading to a total proceeds amounting to SEK 775,204.50. This substantial financial influx reflects a strategic move that not only enhances Sobi's capital resources but also aligns with its long-term goals.

The primary intention behind repurchasing these class C shares is to convert them into common shares. This conversion is stipulated in the company's articles of association and aims to secure future shares for participants in Sobi's extensive incentive programs. As a result, Sobi will enhance its shareholding from 11,343,749 common shares to 12,756,537 common shares upon completion of these conversions.

Sobi's global footprint expands across Europe, North America, the Middle East, Asia, and Australia, employing around 1,900 individuals. The company’s commitment to unlocking innovative solutions in the rare disease sector is evident in its financial success, reporting a revenue of SEK 26 billion in 2024. The share's ongoing presence on Nasdaq Stockholm (STO SOBI) demonstrates the robust investor confidence in Sobi's strategic direction.

This successful completion of class C shares issues is a testament to Sobi's dedication to not only meeting its financial obligations but also maintaining a competitive edge in the biopharma landscape. The decision to convert repurchased shares into common stocks ensures that Sobi is well-positioned to deliver value to its stakeholders while enhancing its capacity to attract and retain talent through its incentive programs. As Sobi continues to progress, the biopharmaceutical community and investors alike will be keenly observing its next steps as it strives to transform the lives of those dealing with rare diseases.

For further insights into Sobi’s operations and future plans, interested parties can visit Sobi's official website or follow them on LinkedIn. The ongoing dialogue regarding Sobi's innovations and initiatives paints a promising picture for the future of rare disease treatment and corporate growth.

In conclusion, the successful issuance and planned conversion of class C shares underlines Sobi's proactive measures in solidifying its operational mechanisms and preparing for future challenges in the fast-paced biopharmaceutical industry.